智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到了欧洲药品管理局(European Medicines Agency,简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请,这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT),治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。
智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到了欧洲药品管理局(European Medicines Agency,简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请,这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT),治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.